Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMP 514

Next Previous
X
Search
Drug Profile

AMP 514

Alternative Names: AMP-514; MEDI-0680

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amplimmune
  • Developer Amplimmune; AstraZeneca; MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B-cell lymphoma
  • Discontinued Solid tumours

Most Recent Events

  • 17 Mar 2020 MedImmune completes a phase I/II trial in Solid tumours (Late-stage disease, Combination therapy) in USA, United Kingdom, Netherlands, France, Canada, Australia (IV) (NCT02118337)
  • 27 Sep 2019 Efficacy and adverse event data from a phase I/II trials in Solid tumours presented at the 44th European Society for Medical Oncology Congress (ESMO-2019)
  • 09 Feb 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV) before February 2018 (MedImmune pipeline, February 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top